RxDoctor Payments Data

Todd Lewis, MD

Cardiovascular Disease · St Augustine, FLNPI 1245274505

Payments from drug & device makers

$475,706in general payments, 2019–2025

Across 821 payments — averaging $579.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$271K
  • Boehringer Ingelheim$176K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$5K
  • Novartis$4K
  • Cardiovascular Systems Inc.$2K
  • Johnson & Johnson$2K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$3,41014%
  • Travel & lodging$8573%
  • Food & beverage$20,53081%
  • Education$4112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca37$270,885
Boehringer Ingelheim32$175,502
Boehringer Ingelheim Pharma GmbH & Co.kg4$4,676
Novartis71$4,092
Cardiovascular Systems Inc.67$2,479
Johnson & Johnson(2 entities)63$1,546
Actelion Pharmaceuticals US, Inc.49$1,345
Abiomed17$1,231
Shockwave Medical, Inc38$1,134
Pfizer42$1,103
United Therapeutics Corporation24$1,034
Amgen58$995
Abbott22$984
Medtronic(2 entities)30$946
Boston Scientific20$859
Merck31$759
Bayer31$710
Boehringer Ingelheim France S.a.s.5$388
Esperion Therapeutics, Inc.19$383
Angiodynamics, Inc.12$357
Novo Nordisk18$343
Penumbra, Inc.10$278
Astellas Pharma US Inc4$243
Biotronik Inc.7$239
Arteriocyte Medical Systems, Inc.2$237
Boehringer Ingelheim Canada Ltd.ltee4$233
Sanofi-aventis U.S. LLC12$224
Amarin Pharma, Inc.13$221
GE HealthCare3$218
Integra Lifesciences Corporation2$205
Stryker4$157
Edwards Lifesciences1$131
Chiesi USA, Inc.7$114
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)7$112
CMS Imaging, Inc.1$106
Philips North America LLC2$105
E.r. Squibb & Sons, L.L.C.6$100
Baxter Healthcare5$89
Regeneron Healthcare Solutions, Inc.4$80
Avinger Inc.1$77
Bard Peripheral Vascular, Inc.2$75
Cardiva Medical, Inc.3$68
Scpharmaceuticals Inc.3$68
Acist Medical Systems, Inc.3$65
Alnylam Pharmaceuticals Inc.3$59
Daiichi Sankyo Inc.2$49
Kiniksa Pharmaceuticals, Ltd.2$46
Teleflex LLC2$45
Sanofi2$41
Recor Medical Inc1$33
Irhythm Technologies, Inc.2$32
Kiniksa Pharmaceuticals International, PLC1$30
Inspire Medical Systems, Inc.1$29
Bristol Myers Squibb1$27
Bardy Diagnostics, Inc.2$26
Lexicon Pharmaceuticals, Inc.1$18
Livanova USA, Inc.1$17
Lilly USA, LLC1$16
GSK1$16
Kestra Medical Technology Services, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$475,706 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,003,735
Medicare patients
1,124
Services billed
6,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$280,461
XareltoRivaroxaban236$277,629
OpsumitMacitentan22$275,502
AdempasRiociguat19$259,925
EntrestoSacubitril/Valsartan112$148,291
JardianceEmpagliflozin122$137,803
Repatha SureclickEvolocumab65$59,493
BrilintaTicagrelor65$43,865
FarxigaDapagliflozin Propanediol31$34,172
OzempicSemaglutide29$34,133
VerquvoVericiguat17$22,993
Repatha SyringeEvolocumab22$20,934
Dofetilide30$13,311
Rosuvastatin Calcium834$11,879
Ezetimibe393$10,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,103$280,461239 claims
Johnson & JohnsonXarelto$1,546$277,629236 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,345$275,50222 claims
BayerAdempas$710$259,92519 claims
NovartisEntresto$4,092$148,291112 claims
Boehringer IngelheimJardiance$175,502$137,803122 claims
AstraZenecaBrilinta, Farxiga$270,885$78,03896 claims
Novo NordiskOzempic$343$34,13329 claims
MerckVerquvo$759$22,99317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →